ATE314462T1 - Verfahren zur transformation dendritischer zellen und aktivierung von t zellen - Google Patents

Verfahren zur transformation dendritischer zellen und aktivierung von t zellen

Info

Publication number
ATE314462T1
ATE314462T1 AT97905877T AT97905877T ATE314462T1 AT E314462 T1 ATE314462 T1 AT E314462T1 AT 97905877 T AT97905877 T AT 97905877T AT 97905877 T AT97905877 T AT 97905877T AT E314462 T1 ATE314462 T1 AT E314462T1
Authority
AT
Austria
Prior art keywords
cells
cell
activation
dendritic
transforming
Prior art date
Application number
AT97905877T
Other languages
English (en)
Inventor
Patrick Hwu
Mark Reeves
Steven A Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE314462T1 publication Critical patent/ATE314462T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97905877T 1996-02-08 1997-02-07 Verfahren zur transformation dendritischer zellen und aktivierung von t zellen ATE314462T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1143396P 1996-02-08 1996-02-08
PCT/US1997/002063 WO1997029183A2 (en) 1996-02-08 1997-02-07 Methods and compositions for transforming dendritic cells and activating t cells

Publications (1)

Publication Number Publication Date
ATE314462T1 true ATE314462T1 (de) 2006-01-15

Family

ID=21750351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905877T ATE314462T1 (de) 1996-02-08 1997-02-07 Verfahren zur transformation dendritischer zellen und aktivierung von t zellen

Country Status (7)

Country Link
EP (1) EP0879281B1 (de)
JP (1) JP2000505650A (de)
AT (1) ATE314462T1 (de)
AU (1) AU730537B2 (de)
CA (1) CA2245170A1 (de)
DE (1) DE69734974D1 (de)
WO (1) WO1997029183A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510046A (ja) * 1995-07-21 1999-09-07 ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7351546B2 (en) 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
EP1165144A2 (de) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Mit einem eigengen-wildtyp transduzierte dendritische zellen lösen starke antitumor immunantwort aus
EP1046911A1 (de) * 1999-04-23 2000-10-25 Universiteit van Amsterdam Methoden zur Identifizierung von Substanzen, die zelluläre Reaktionen auslösen können
WO2000073432A2 (en) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
FR2795415B1 (fr) 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
US7988963B1 (en) * 1999-10-15 2011-08-02 Baylor Research Institute Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7767202B2 (en) * 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
JP2004538331A (ja) * 2001-08-17 2004-12-24 ロジャー ウィリアムス ホスピタル インサイチュ免疫法
US7955845B2 (en) 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2006124700A2 (en) 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
US20110313229A1 (en) * 2008-07-24 2011-12-22 Kiminobu Sugaya Therapy Targeting Cancer Stem Cells
EP2601521B1 (de) * 2010-08-06 2018-05-02 Ludwig-Maximilians-Universität München Identifizierung von t-zell-zielantigenen
US20150118265A1 (en) * 2012-03-13 2015-04-30 Anthrogenesis Corporation Modified erythrocyte precursor cells and uses thereof
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
CA2131368A1 (en) * 1992-03-04 1993-09-16 Chu-Chih Shih Culturing of hematopoietic stem cells and their genetic engineering
EP0563485A1 (de) * 1992-03-30 1993-10-06 Schering-Plough In-vitro-Erzeugung von menschlichen dendritischen Zellen
JPH09500013A (ja) * 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
ES2201102T3 (es) * 1994-06-15 2004-03-16 Systemix, Inc. Poblaciones de celulas enriquecidas en progenitores mieloides y/o linfoides y metodos de elaboracion y uso.
JPH11510046A (ja) * 1995-07-21 1999-09-07 ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用

Also Published As

Publication number Publication date
WO1997029183A3 (en) 1997-12-18
CA2245170A1 (en) 1997-08-14
AU2266097A (en) 1997-08-28
EP0879281A2 (de) 1998-11-25
JP2000505650A (ja) 2000-05-16
WO1997029183A2 (en) 1997-08-14
DE69734974D1 (de) 2006-02-02
EP0879281B1 (de) 2005-12-28
AU730537B2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
DE69734974D1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
EP1427744A4 (de) System zur antikörperexpression und- synthese
DE69732407D1 (de) Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
WO2002020569A3 (en) Mammalian genes; related reagents and methods
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
ATE194291T1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
PT93966A (pt) Novo sistema de libertacao de anticorpos para modificadores de resposta biologica
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
ATE320265T1 (de) Staphylococcus-antigene und impstoff
AU4626596A (en) Process for preparing macrophages, and kits and compositions therefore
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
WO1999036568A3 (de) Verfahren zum identifizieren von t-zell-stimulierenden proteinfragmenten
AR022236A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
WO1999064464A3 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
AR022237A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
AU1060397A (en) High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
AU1825097A (en) Mammalian cx3c chemokine genes
BR9713450A (pt) Quimiocinas de mamìfero
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
MXPA02004825A (es) Genes especificamente expresados en celulas dendriticas humanas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties